Bruker Corp (BRKR)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
- Symbol
- BRKR
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $9.09B
- 52 week range
- 30.09 - 65.3
Valuation
- Share price
- $59.59 (close of 2026-09-23)
- P/E (TTM)
- -85.24x
- Price to book
- 3.79x
- Price to free cash flow
- 96.81x
- Enterprise value
- $10.73B
- Book value per share
- $15.75
Price performance
| Period | Change |
|---|
| 1 day | -3.23% |
| 5 days | +6.89% |
| 1 month | +0.05% |
| 3 months | +8.13% |
| 6 months | +70.94% |
| Year to date | +26.49% |
| 1 year | +78.90% |
| 3 years | -4.21% |
| 5 years | -29.79% |
| 10 years | +166.38% |
| All time | +158.41% |
Profitability and growth
- Return on equity
- -0.35%
- Return on invested capital
- 0.92%
- Return on assets
- -0.14%
- Return on capital employed
- 1.37%
- Gross margin
- 45.91%
- Net margin
- -0.25%
- EBITDA margin
- 8.40%
- Revenue growth
- 2.08%
- Net income growth
- -107.60%
- Free cash flow growth
- -68.16%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 1.03%
- Current ratio
- 1.85x
- Net debt to EBITDA
- 6.09x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $3.44B
- Cost of revenue
- $1.86B
- Gross profit
- $1.58B
- EBITDA
- $288.50M
- Net income
- $-8.60M
- Earnings per share
- $-0.15
- Research and development
- $395.20M
- Shares outstanding
- 151.80M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $3.44B | $1.58B | $-8.60M | $-0.15 |
| 2024-12-31 | $3.37B | $1.65B | $113.10M | $0.76 |
| 2023-12-31 | $2.96B | $1.51B | $427.20M | $2.92 |
| 2022-12-31 | $2.53B | $1.31B | $296.60M | $2.00 |
| 2021-12-31 | $2.42B | $1.21B | $277.10M | $1.83 |
| 2020-12-31 | $1.99B | $939.80M | $157.80M | $1.03 |
| 2019-12-31 | $2.07B | $995.30M | $197.20M | $1.27 |
| 2018-12-31 | $1.90B | $900.00M | $179.70M | $1.15 |
| 2017-12-31 | $1.77B | $816.00M | $78.60M | $0.50 |
| 2016-12-31 | $1.61B | $745.30M | $153.60M | $0.95 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 45.91% | -0.25% | -0.35% | 0.92% |
| 2024-12-31 | 49.00% | 3.36% | 6.29% | 4.19% |
| 2023-12-31 | 51.05% | 14.41% | 30.63% | 13.96% |
| 2022-12-31 | 51.59% | 11.72% | 26.35% | 18.07% |
| 2021-12-31 | 50.03% | 11.46% | 25.55% | 24.98% |
| 2020-12-31 | 47.29% | 7.94% | 16.20% | 15.90% |
| 2019-12-31 | 48.02% | 9.51% | 21.50% | 19.61% |
| 2018-12-31 | 47.48% | 9.48% | 19.85% | 21.95% |
| 2017-12-31 | 46.21% | 4.45% | 10.72% | 22.43% |
| 2016-12-31 | 46.25% | 9.53% | 22.16% | 43.62% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $298.80M | $1.85B |
| 2024-12-31 | $183.40M | $2.06B |
| 2023-12-31 | $488.30M | $1.16B |
| 2022-12-31 | $645.50M | $1.20B |
| 2021-12-31 | $1.17B | $1.22B |
| 2020-12-31 | $731.80M | $842.30M |
| 2019-12-31 | $684.90M | $812.80M |
| 2018-12-31 | $322.40M | $322.60M |
| 2017-12-31 | $439.20M | $195.00M |
| 2016-12-31 | $500.30M | $171.00M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $43.30M | $20.20M |
| 2024-12-31 | $136.00M | $25.30M |
| 2023-12-31 | $243.20M | $30.90M |
| 2022-12-31 | $145.20M | $27.70M |
| 2021-12-31 | $190.40M | $17.20M |
| 2020-12-31 | $235.00M | $16.00M |
| 2019-12-31 | $140.40M | $9.60M |
| 2018-12-31 | $190.50M | $11.30M |
| 2017-12-31 | $110.70M | $11.00M |
| 2016-12-31 | $93.70M | $9.40M |
Dividend history
- Most recent payment
- 2026-09-21
- Paid in the last twelve months
- $0.20
| Payment date | Dividend per share |
|---|
| 2026-09-21 | $0.05 |
| 2026-06-22 | $0.05 |
| 2026-03-23 | $0.05 |
| 2025-12-08 | $0.05 |
| 2025-09-23 | $0.05 |
| 2025-06-16 | $0.05 |
| 2025-03-17 | $0.05 |
| 2024-12-02 | $0.05 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-02
- Consensus EPS estimate
- $0.42
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-04 | Jun/2026 | $0.38 |
| 2026-05-06 | - | - |
| 2026-02-12 | - | - |
| 2025-11-03 | - | - |
| 2025-08-04 | - | - |
| 2025-05-07 | - | - |
| 2025-02-13 | - | - |
| 2025-01-06 | - | - |
Filings and sources
- Company website
- bruker.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Abbott Laboratories (ABT) · Medtronic plc (MDT) · Stryker Corp (SYK) · Boston Scientific Corp (BSX) · Edwards Lifesciences Corp (EW) · Dexcom Inc (DXCM) · STERIS plc (STE) · Zimmer Biomet Holdings, Inc. (ZBH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades